Compounds > vinyl sulfonamide
Page last updated: 2024-11-08

vinyl sulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vinyl sulfonamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID520075
CHEMBL ID5175910
SCHEMBL ID50770
MeSH IDM0406571

Synonyms (19)

Synonym
ethylenesulfonamide
vinylsulfonamide
ethenesulfonamide
EN300-79721
2386-58-5
AKOS006229906
SCHEMBL50770
vinyl sulfonamide
ethenesulphonamide
ethenesulfonic acid amide
ethylenesulfonamide #
DTXSID90334240
CHEMBL5175910
BS-12675
mfcd00051751
CS-0091212
D75049
SY058285
Z1198149166
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1902022Inhibition of tau K18 domain (unknown origin) assessed as inhibition of heparin-induced aggregation by measuring protein aggregation rate at 10 uM by thioflavin-T fluorescence assay relative to control2022European journal of medicinal chemistry, Mar-05, Volume: 231A covalent strategy to target intrinsically disordered proteins: Discovery of novel tau aggregation inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's4 (44.44)24.3611
2020's3 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.99 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acrylamide
[no description available]		2.110acrylamides;
N-acylammonia;
primary carboxamide		alkylating agent;
carcinogenic agent;
Maillard reaction product;
mutagen;
neurotoxin
phenyl vinyl sulfone
phenyl vinyl sulfone: RN and structure in first source		2.4110
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		2.0810stilbene
beta-sultam
beta-sultam: structure in first source		2.4720
ConditionIndicatedRelationship StrengthStudiesTrials
Degenerative Diseases, Central Nervous System
[description not available]		02.4110
Tauopathies
Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.		02.4110
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		02.4110